Surrozen (NASDAQ:SRZN) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Surrozen (NASDAQ:SRZN) in a report issued on Thursday, MarketBeat Ratings reports. The firm issued a buy rating and a $32.00 price objective on the stock.

Separately, Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, January 3rd.

Surrozen Trading Up 7.3 %

Shares of SRZN opened at $12.07 on Thursday. The firm’s 50-day simple moving average is $11.51 and its 200 day simple moving average is $10.12. Surrozen has a 52 week low of $6.00 and a 52 week high of $18.17.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The business had revenue of $10.00 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Surrozen stock. Stonepine Capital Management LLC boosted its holdings in shares of Surrozen, Inc. (NASDAQ:SRZN) by 66.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the company’s stock after acquiring an additional 43,916 shares during the quarter. Surrozen accounts for about 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 24th largest position. Stonepine Capital Management LLC owned 3.43% of Surrozen worth $1,318,000 at the end of the most recent quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.